Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'

April 27, 2026 10:48 AM EDT

TD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "NTLA released Ph. III data of its in vivo gene editing candidate lonvo-z for the treatment of HAE this morning. The trial hit both primary and... More